Membranoproliferative glomerulonephritis secondary prevention

Revision as of 20:24, 6 August 2018 by Aditya Ganti (talk | contribs)
Jump to navigation Jump to search

Membranoproliferative glomerulonephritis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Membranoproliferative glomerulonephritis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Membranoproliferative glomerulonephritis secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Membranoproliferative glomerulonephritis secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Membranoproliferative glomerulonephritis secondary prevention

CDC on Membranoproliferative glomerulonephritis secondary prevention

Membranoproliferative glomerulonephritis secondary prevention in the news

Blogs on Membranoproliferative glomerulonephritis secondary prevention

Directions to Hospitals Treating Membranoproliferative glomerulonephritis

Risk calculators and risk factors for Membranoproliferative glomerulonephritis secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief:

Overview

Secondary prevention of strategy is a method to reduce the complication of disease, and one of the most important complication of MPGN is end-stage renal disease (ESRD).

Secondary prevention

Risk factors that can predict the progression of the disease to ESRD are included:[1]

  • Proteinuria
  • Systemic hypertension
  • Progressive decline in GFR

When these risk factors have been seen through the natural history of each individual, secondary prevention strategy have been initiate to reduce the chance of ESRD.

Through secondary prevention, these medication should be taken:

  • Angiotensin-converting enzyme (ACE) inhibitors
  • Angiotensin-receptor blockers
  • Combined ACE inhibition and angiotensin receptor antagonism
  • Dietary protein restriction

References

  1. Kambiz Zandi-Nejad, and Barry M. Brenner. "Primary and secondary prevention of chronic kidney disease". Journal of hypertension. 23: 10.

Template:WH Template:WS